Trial record 1 of 1 for:    Breast BRE09-146
Previous Study | Return to List | Next Study

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Clovis Oncology, Inc.
Information provided by (Responsible Party):
Hoosier Cancer Research Network
ClinicalTrials.gov Identifier:
NCT01074970
First received: February 23, 2010
Last updated: August 20, 2014
Last verified: August 2014

February 23, 2010
August 20, 2014
February 2010
May 2013   (final data collection date for primary outcome measure)
Two-year Disease Free Survival [ Time Frame: 24 months ] [ Designated as safety issue: No ]
To evaluate 2-year disease-free survival (DFS), in patients with confirmed TNBC or ER/PR + HER2-, known BRCA1/2 mutations treated with single agent cisplatin and patients treated with cisplatin in combination with Rucaparib following preoperative chemotherapy
Two-year Disease Free Survival [ Time Frame: 24 months ] [ Designated as safety issue: No ]
To evaluate 2-year disease-free survival (DFS), in patients with confirmed TNBC or ER/PR + HER2-, known BRCA1/2 mutations treated with single agent cisplatin and patients treated with cisplatin in combination with PF 01367338 following preoperative chemotherapy
Complete list of historical versions of study NCT01074970 on ClinicalTrials.gov Archive Site
  • Side Effects and Tolerability [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    To characterize the side effects and tolerability of cisplatin and cisplatin plus Rucaparib in patients with residual disease following preoperative chemotherapy.
  • One-year Disease Free Survival [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    To evaluate 1-year DFS
  • Overall Survival [ Time Frame: 60 months ] [ Designated as safety issue: No ]
    To determine 5-year overall survival
  • Pharmacokinetic Data [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    To collect limited pharmacokinetic data, in patients receiving study drug to compliment ongoing PK analyses in other trials with Rucaparib
  • Specimen Collection [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    To collect peripheral blood lymphocytes, archived tumor specimens, and genomic DNA to explore potential correlates of PARP inhibition, recurrence and toxicity.
  • Side Effects and Tolerability [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    To characterize the side effects and tolerability of cisplatin and cisplatin plus PF 01367338 in patients with residual disease following preoperative chemotherapy.
  • One-year Disease Free Survival [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    To evaluate 1-year DFS
  • Overall Survival [ Time Frame: 60 months ] [ Designated as safety issue: No ]
    To determine 5-year overall survival
  • Pharmacokinetic Data [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    To collect limited pharmacokinetic data, in patients receiving study drug to compliment ongoing PK analyses in other trials with PF 01367338
  • Specimen Collection [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    To collect peripheral blood lymphocytes, archived tumor specimens, and genomic DNA to explore potential correlates of PARP inhibition, recurrence and toxicity.
Not Provided
Not Provided
 
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146

The purpose of this trial is to evaluate 2-year disease-free survival in this patient population treated with single agent cisplatin and patients treated with cisplatin in combination with Rucaparib following preoperative chemotherapy. Side effects and tolerability of this treatment in patients with residual disease following preoperative chemotherapy will also be observed and characterized.

OUTLINE: This is a multi-center study.

Safety Run-in will be for the first 12 patients on study only (6 in cohort 1 and 6 in cohort 2). Patients in the safety run will be included in the efficacy analysis on intent to treat basis:

Cisplatin 75 mg/m2 IV D1 every 3 weeks x 4 cycles; Rucaparib 16-30 mg IV D 1,2,3 every 3 weeks x 4 cycles

If cycle 1 is well tolerated, the dose of Rucaparib will be escalated from 16 mg to 24 mg for subsequent cycles in the cohort 1, and 24 mg to 30 mg in the cohort 2.

If ≤ 1 of 6 patients in cohort 1 experiences DLT, cohort 2 will commence. If 2 or more of 6 patients in cohort 1 experience DLT, the study will be suspended and an amendment to explore lower doses will be considered.

If ≤ 1 of 6 patients in cohort 2 experiences DLT, the randomized portion of the study will commence. If 2 or more of 6 patients experience DLT, the study will be suspended and an amendment to proceed with the randomized portion at the cohort 2 dose (24 mg) will be considered.

During the randomized portion of the study, patients will be randomized to either Arm A or Arm B.

Stratification factors:

  • Anthracycline vs. not
  • Residual LN involvement vs. No Residual LN involvement

Arm A (Cisplatin Monotherapy) Cisplatin 75 mg/m2 IV D1 every 3 weeks x 4 cycles

Arm B (Combination Therapy) Cisplatin 75 mg/m2 IV D1 every 3 weeks x 4 cycles; Rucaparib 16-30 mg IV D1,2,3 every 3 weeks x 4 cycles

Rucaparib maintenance 30 mg IV weekly x 24 weeks

ECOG Performance Status 0-1

Life Expectancy: Not Specified

Hematopoietic:

  • Hemoglobin (Hgb) > 9.0 g/dL
  • Platelets > 100 K/ mm3
  • Absolute neutrophil count (ANC) > 1.5 K/mm3

Hepatic:

  • Bilirubin < upper limit of normal (except in patients with documented Gilbert's disease, who must have a total bilirubin < 3.0 mg/dL)
  • Aspartate aminotransferase (AST, SGOT) < 2.5 x ULN
  • Alanine aminotransferase (ALT, SGPT) < 2.5 x ULN

Renal:

  • Calculated creatinine clearance of > 50 cc/min using the Cockcroft-Gault formula

Cardiovascular:

  • Left ventricular ejection fraction within normal limits.
  • Patients with an unstable angina or myocardial infarction within 12 months of study entry are excluded.
  • No clinically significant arrhythmia or baseline ECG abnormalities in the opinion of the treating investigator.
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Breast Cancer
  • Drug: Cisplatin
    Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
  • Drug: Rucaparib
    Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles
  • Active Comparator: Arm A: Cisplatin Monotherapy
    Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
    Intervention: Drug: Cisplatin
  • Active Comparator: Arm B: Combination Therapy

    Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles

    Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles

    Interventions:
    • Drug: Rucaparib
    • Drug: Cisplatin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
135
May 2015
May 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Must have histologically or cytologically confirmed triple negative (ER-/PR-/HER2-) invasive breast cancer, stage I-III at diagnosis (AJCC 6th edition) based on initial evaluation by clinical examination and/or breast imaging. NOTE: Patients with ER+ and/or PR+ may enroll ONLY if they are known carriers of a deleterious mutation in BRCA1 or BRCA2. Patients with HER2+ tumors may not enroll regardless of BRCA status.
  • Must have completed preoperative (neoadjuvant) chemotherapy. NOTE: Acceptable preoperative regimens include an anthracycline or a taxane, or both. Patients may NOT have received cisplatin as part of their neoadjuvant therapy regimen. Patients who received preoperative therapy as part of a clinical trial may enroll. No adjuvant chemotherapy after surgery other than that specified in this protocol is allowed. Adjuvant bisphosphonate use is allowed.
  • Must have completed definitive resection of primary tumor. The last surgery for breast cancer must have been completed at least 14 days prior to registration for protocol therapy.
  • Must have significant residual invasive disease at the time of definitive surgery following preoperative chemotherapy. Significant residual disease is defined at least one of the following:

    • Miller-Payne response in the breast of 0-25.
    • Residual Cancer Burden (RBC) classification II or III6
    • Residual carcinoma in one or more regional lymph nodes that would meet AJCC 6th edition criteria for N1 - N3 disease.
    • Alternatively, if Miller-Payne or RCB grading is not available, the patient will be eligible if the pathology report indicates that the area of residual invasive disease in the breast measures at least 2 cm following preoperative therapy. The presence of DCIS without invasion does not qualify as residual disease in the breast.
  • Whole breast radiotherapy is required for patients who underwent breast conserving therapy, including lumpectomy or partial mastectomy. Patients receiving adjuvant radiation therapy must have completed radiotherapy at least 14 days prior to registration for protocol therapy.
  • Written informed consent and HIPAA authorization for release of personal health information.
  • Age > 18 years at the time of consent.
  • Must consent to allow submission of archived tumor tissue sample from definitive surgery.
  • Must consent to collection of blood samples for PK analysis.
  • Women of childbearing potential and males must be willing to use an effective method of contraception from the time consent is signed until 4 weeks after treatment discontinuation.
  • Women of childbearing potential must have a negative pregnancy test within 14 days prior to registration for protocol therapy.
  • Women must not be breastfeeding.

Exclusion Criteria:

  • No stage IV (metastatic) disease, however no specific staging studies are required in the absence of symptoms or physical exam findings that would suggest distant disease.
  • No treatment with any investigational agent within 30 days prior to registration for protocol therapy.
  • No history of chronic hepatitis B or C
  • No clinically significant infections as judged by the treating investigator.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01074970
BRE09-146
Yes
Hoosier Cancer Research Network
Hoosier Cancer Research Network
Clovis Oncology, Inc.
Study Chair: Kathy D. Miller, M.D. Hoosier Cancer Research Network
Hoosier Cancer Research Network
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP